Welcome to our dedicated page for Indivior Pharmaceuticals news (Ticker: INDV), a resource for investors and traders seeking the latest updates and insights on Indivior Pharmaceuticals stock.
Indivior Pharmaceuticals, Inc. reports developments in specialty pharmaceuticals for opioid use disorder, with recurring updates centered on SUBLOCADE, its monthly extended-release buprenorphine injection, and evidence supporting medications for opioid use disorder. Company news commonly covers financial results and guidance, commercial performance for SUBLOCADE, scientific and real-world evidence studies, and treatment-use discussions in settings such as correctional facilities.
Indivior updates also include capital-allocation actions, including share repurchase programs and convertible note financing, along with corporate presentations and investor communications tied to the Indivior Action Agenda. The company’s disclosures frame opioid use disorder as a chronic treatable brain disease and emphasize buprenorphine-based prescription treatments.
Indivior (NASDAQ: INDV) will participate in the Piper Sandler 37th Annual Healthcare Conference in New York City on December 2, 2025. Chief Executive Officer Joe Ciaffoni and Chief Financial Officer Ryan Preblick will host 1x1 and group meetings and will join a fireside discussion at 3:30 p.m. ET on the same day. Interested investors should contact their Piper Sandler representative to schedule meetings. The fireside discussion will be publicly available via the Piper Sandler Fireside Chat Live Webcast.
Indivior (Nasdaq: INDV) presented three real-world evidence posters at AMCP Nexus 2025 on Nov 3, 2025 showing clinical and economic benefits of monthly injectable buprenorphine SUBLOCADE for opioid use disorder.
Key findings: lower relapse and recurrence rates, reduced emergency and inpatient use, and substantially lower medical costs in high-adherence patients across Medicaid and commercial cohorts (example: total medical costs ~$23,051 vs $43,357). Analyses also reported lower infectious complications (skin infections -37%, bacteremia -62%) versus transmucosal buprenorphine. Limitations include retrospective claims/EHR design, lack of baseline adjustments, and overlap with the COVID-19 period.
Indivior (NASDAQ: INDV) reported Q3 2025 results and raised full-year guidance on Oct 30, 2025. Total net revenue was $314m in Q3 (+2% YoY) and SUBLOCADE net revenue was $219m (+15% YoY). The company raised FY2025 revenue guidance to $1.18–1.22bn and adjusted EBITDA to $400–420m. Management expects at least $150m of annual operating expense savings beginning 2026 after organizational simplification and ROW optimization. Q3 non-GAAP gross margin was 84% and adjusted EBITDA was $120m. Actions include ROW market exits, discontinuing OPVEE commercial support, and an intended U.S. redomicile.
Indivior (NASDAQ: INDV) will participate in the Stifel 2025 Healthcare Conference in New York City.
Chief Executive Officer Joe Ciaffoni and Chief Financial Officer Ryan Preblick will host 1x1 and group meetings and will appear in a public fireside discussion on Thursday, November 13, 2025 at 8:40 a.m. U.S. EST. Interested investors should contact their Stifel representative to schedule meetings. The fireside discussion will be available via a public webcast.
Indivior (Nasdaq: INDV) will report its third quarter 2025 financial results on Thursday, October 30, 2025 at 7:00 a.m. U.S. ET. Following the release, CEO Joe Ciaffoni and other leaders will host a live webcast presentation at 8:00 a.m. U.S. ET. The live webcast and presentation materials will be available on the company's Investors page at www.indivior.com, with a live webcast link and telephone registration option provided for participants. A replay of the presentation will be posted on www.indivior.com after the event.
Indivior (Nasdaq: INDV) published multicenter, open-label trial results in JAMA Network Open on Oct 15, 2025 showing that rapid SUBLOCADE induction (single 4 mg oral buprenorphine followed by same-day SUBLOCADE injection) was well tolerated and produced higher retention at the second injection versus standard induction (≥7 days oral buprenorphine before first injection).
Benefits were seen across the study population and were especially pronounced among fentanyl-positive participants. Administering the second SUBLOCADE injection one week after the first was well tolerated and the safety profile up to injection two was comparable between arms. Study limitations include its open-label design, which could introduce reporting bias.
Indivior (Nasdaq: INDV) has announced plans to change its corporate domicile from the U.K. to the U.S., establishing Indivior Pharmaceuticals, Inc. (IPI) as the new U.S. parent company. This strategic move follows the company's Nasdaq listing in June 2023 and subsequent delisting from the London Stock Exchange in July 2025.
The redomiciliation will be implemented through a U.K. court-sanctioned scheme of arrangement, where shareholders will receive one new IPI share for each Indivior PLC share. The transaction requires shareholder approval at an extraordinary general meeting in early December 2025, with the scheme expected to become effective in late January 2026. IPI shares will continue trading on Nasdaq under the symbol INDV.
Indivior (NASDAQ: INDV) announced its participation in two upcoming investor conferences in New York City. At the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8th, CEO Joe Ciaffoni and CFO Ryan Preblick will host meetings and participate in a fireside chat at 9:15 a.m. ET. The following day, September 9th, the executives will attend the H.C. Wainwright 27th Annual Global Investment Conference for one-on-one and group meetings.
Indivior (NASDAQ: INDV) reported strong Q2 2025 financial results and raised its full-year guidance. Total net revenue reached $302 million, with SUBLOCADE net revenue growing 9% year-over-year to $209 million. The company has increased its FY 2025 guidance, raising total net revenue expectations to $1,030-$1,080 million from $955-$1,025 million, and adjusted EBITDA guidance to $275-$300 million from $220-$260 million.
Key Q2 metrics include gross margin of 83%, net income of $18 million, and diluted EPS of $0.14. The company initiated its Indivior Action Agenda focusing on SUBLOCADE growth and organizational simplification, completed its LSE delisting to trade exclusively on Nasdaq, and strengthened its executive team with new appointments.
[ "SUBLOCADE Q2 net revenue grew 9% YoY to $209M, with 19% growth vs Q1'25", "Company raised FY 2025 guidance with $65M increase in revenue expectations", "Adjusted EBITDA guidance increased by $48M at midpoint", "Strong cash position of $538M, up $191M from end of 2024", "Pricing stability achieved in SUBOXONE Film U.S. market" ]Indivior (Nasdaq: INDV) has completed the cancellation of its secondary listing on the London Stock Exchange effective July 25, 2025 at 8:00 a.m. UK time. The delisting includes the removal from both the UK Financial Conduct Authority's Official List and the London Stock Exchange's main market for listed securities.
The company will maintain its primary listing on the Nasdaq Stock Market. To assist shareholders with this transition, Indivior has made available an FAQ document on their investor relations website.